Please Complain: FDA Needs GDUFA Meeting Comments, Presenters
This article was originally published in The Pink Sheet Daily
Agency officials indicate feedback is critical as generic drug user fee program enters its third year and applications go on the clock in earnest.
You may also be interested in...
U.S. FDA officials still looking for input after transparency issue not widely addressed during GDUFA policy meeting.
FDA wants to know whether 180-day exclusivity should be revealed up front; question is one of many on ANDA reviews to be considered at September public hearing.
Small business owners say the GDUFA facility and other fees are too expensive, especially while waiting for ANDAs to be approved, but any small business waiver is unlikely until GDUFA II.